M
e MENOPAUSE PRACTICE QUESTIONS &
VERIFIED UPDATED ANSWERS 100%
1. JW, a 53-year-old post-menopausal female, presents to
A. the pharmacy with a new prescription for 17β-
estradi- ol topical gel (EstroGel) for vasomotor
symptom relief.
Which of the following is the appropriate administra-
tion of 17β- estradiol topical gel (EstroGel)?
A. Apply 1 pump depression once daily to one
arm from wrist to shoulder
B. Apply 1 pump depression once daily to one
upper arm and shoulder area
C. Apply 1 packet once daily to one upper thigh
D. Apply 1 pouch once daily to each thigh and calf
2. JW, a 53-year-old post-menopausal female, presents to C.
the pharmacy with a new prescription for 17β-
estradi- ol topical gel (EstroGel) for vasomotor
symptom relief.
Which statement should be included in the
counseling for 17β- estradiol topical gel (EstroGel)?
A. Apply gel after applying lotion, powder, or oil
B. Washing hands after application is not necessary
C. Allow gel to dry before dressing
D. Massage or rub in gel after application
3. CG is a 55-year-old post-menopausal woman seeking
C. treatment for vasomotor symptoms. She has an
intact uterus and a history of breast cancer.
Which of the following patient data is an absolute
con- traindication to hormone replacement
therapy?
1/
12
,M
e MENOPAUSE PRACTICE QUESTIONS &
VERIFIED UPDATED ANSWERS 100%
A. Former smoker
B. Current treatment for type 2 diabetes
C. History of breast cancer
D. Family history of CHD
4. CG is a 55-year-old post-menopausal woman seeking
B. treatment for vasomotor symptoms. She has an
intact uterus and a history of breast cancer.
Which treatment is most appropriate for this patient?
A. Micronized 17β- estradiol (Estrace)
B. Venlafaxine (Effexor)
C. Ospemifene (Osphena)
D. Raloxifene (Evista)
5. HC, a 52-year-old female, has been prescribed a A.
continuous combined oral estrogen and progesto-
gen product for vasomotor symptom relief related
to menopause. She has read about the potential
risks associated with HRT and would like to discuss
these before filling the prescription.
Which of the following strategies will help reduce
the incidence of breast cancer?
A. Limit duration of use to 5 years
B. Use bioidentical HRT instead
C. Use transdermal estrogen instead
D. Use phytoestrogens instead
6. HC, a 52-year-old female, has been prescribed a B.
continuous combined oral estrogen and progesto-
2/
12
e MENOPAUSE PRACTICE QUESTIONS &
VERIFIED UPDATED ANSWERS 100%
1. JW, a 53-year-old post-menopausal female, presents to
A. the pharmacy with a new prescription for 17β-
estradi- ol topical gel (EstroGel) for vasomotor
symptom relief.
Which of the following is the appropriate administra-
tion of 17β- estradiol topical gel (EstroGel)?
A. Apply 1 pump depression once daily to one
arm from wrist to shoulder
B. Apply 1 pump depression once daily to one
upper arm and shoulder area
C. Apply 1 packet once daily to one upper thigh
D. Apply 1 pouch once daily to each thigh and calf
2. JW, a 53-year-old post-menopausal female, presents to C.
the pharmacy with a new prescription for 17β-
estradi- ol topical gel (EstroGel) for vasomotor
symptom relief.
Which statement should be included in the
counseling for 17β- estradiol topical gel (EstroGel)?
A. Apply gel after applying lotion, powder, or oil
B. Washing hands after application is not necessary
C. Allow gel to dry before dressing
D. Massage or rub in gel after application
3. CG is a 55-year-old post-menopausal woman seeking
C. treatment for vasomotor symptoms. She has an
intact uterus and a history of breast cancer.
Which of the following patient data is an absolute
con- traindication to hormone replacement
therapy?
1/
12
,M
e MENOPAUSE PRACTICE QUESTIONS &
VERIFIED UPDATED ANSWERS 100%
A. Former smoker
B. Current treatment for type 2 diabetes
C. History of breast cancer
D. Family history of CHD
4. CG is a 55-year-old post-menopausal woman seeking
B. treatment for vasomotor symptoms. She has an
intact uterus and a history of breast cancer.
Which treatment is most appropriate for this patient?
A. Micronized 17β- estradiol (Estrace)
B. Venlafaxine (Effexor)
C. Ospemifene (Osphena)
D. Raloxifene (Evista)
5. HC, a 52-year-old female, has been prescribed a A.
continuous combined oral estrogen and progesto-
gen product for vasomotor symptom relief related
to menopause. She has read about the potential
risks associated with HRT and would like to discuss
these before filling the prescription.
Which of the following strategies will help reduce
the incidence of breast cancer?
A. Limit duration of use to 5 years
B. Use bioidentical HRT instead
C. Use transdermal estrogen instead
D. Use phytoestrogens instead
6. HC, a 52-year-old female, has been prescribed a B.
continuous combined oral estrogen and progesto-
2/
12
